Company intelligence / Profile preview
ECI Therapeutics
Garden City, New York, United Statesecitherapeutics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
ECI Therapeutics is developing a proprietary platform that combines platelet-rich plasma-derived growth factors with chitosan or hyaluronic acid for use in ophthalmic, wound, and burn care. The company’s lead programs target rare ophthalmic diseases such as neurotrophic keratopathy and common conditions like dry eye disease. No clinical trial results have been published yet; products are still under development.[1][2][4]
- Therapeutic areas
- Rare DiseasesCardiovascularOphthalmologyDermatology
- Modalities
- Plasma-derived growth factors (from human platelet-rich plasma)Chitosan-based excipientsHyaluronic acid-based excipients[1][2][5][6]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on ECI Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ECI Therapeutics.